Our results showed that UBE2S transcription is activated by the binding of FOXM1 to UBE2S promoter and dependent on H3K4me3 activation, which enhanced the resistance of HCC cells to 5-FU and oxaliplatin. The gene discussed is UBE2S; the disease is hepatocellular carcinoma.